7 Apr 2022 07:00
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Director's Share Purchase
SourceBio International plc (AIM: SBI), a leading international provider of integrated state-of-the-art laboratory services and products, announces that on 6 April 2022, Jay LeCoque, Executive Chairman, purchased 100,000 Ordinary Shares in the Company at a price of 129.5 pence per Ordinary Share, representing 0.14% of the Company's issued share capital.
Jay LeCoque's total shareholding now comprises 2,444,612 Ordinary Shares, representing 3.30% of the Company's issued share capital.
Contacts:
SourceBio International plc | www.sourcebiointernational.com | |
Jay LeCoque, Executive Chairman | Via Walbrook PR | |
Tony Ratcliffe, Chief Financial Officer | ||
Liberum (Nominated Advisor and Broker) | Tel: 020 3100 2000 | |
Richard Lindley / William Hall | ||
Walbrook PR Limited | Tel: 020 7933 8780 or sourcebio@walbrookpr.com | |
Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 | |
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:
· Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare providers across the UK and Ireland, including Digital Pathology
· Genomics - DNA sequencing services and Precision Medicine offering for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America
· Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA
· Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups and the NHS, including PCR testing under ISO 15189 accreditation. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits and venue testing.
More details on Group operations can be found here: www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||
a)
| Name
|
Jay LeCoque | ||||||
2
| Reason for the notification
| |||||||
a)
| Position/status
| Executive Chairman | ||||||
b)
| Initial notification /Amendment
| Initial Notification | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a)
| Name
| SourceBio International Plc | ||||||
b)
| LEI
| 213800KY4C9WU7WBW518
| ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of £0.0015 each | ||||||
Identification code | GB00BKSB1674
| |||||||
b)
| Nature of the transaction
| Purchase of 100,000 Ordinary Shares
| ||||||
c) | Price(s) and volume(s) |
| ||||||
d)
| Aggregated information
Volume Price |
N/A - single transaction | ||||||
e)
| Date of the transaction
| 6 April 2022 | ||||||
f)
| Place of the transaction
| London Stock Exchange
| ||||||